Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.05 – $0.15
29% from low
Exchange
OTC Link
CS
Borrow rate
0.25%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2004 | 2005 | 2006 | 2007 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.6M | $3.1M | $2.4M | $2.8M | $0 | $58.6K | $66.4K | $310.9K |
| Cost of revenue | $925.8K | $1.9M | $1.3M | $1.9M | $0 | $29.2K | $22.6K | $276.2K |
| Gross profit | $629.9K | $1.2M | $1.1M | $928.0K | $0 | $29.4K | $43.8K | $34.7K |
| Gross margin | 40.5% | 38.3% | 45.3% | 32.9% | — | 50.2% | 66.0% | 11.1% |
| R&D | $181.6K | $98.3K | $374.8K | $392.3K | $0 | $0 | $0 | $0 |
| Operating income | −$430.8K | −$379.1K | −$1.5M | −$2.5M | −$113.3K | −$21.8K | −$139.6K | −$67.8K |
| EBITDA | −$14.2K | $846.2K | −$736.9K | −$1.9M | −$113.3K | $207.6K | $29.8K | −$59.9K |
| Net income | $310.1K | $200.7K | −$1.2M | −$2.4M | −$113.3K | −$21.0K | −$138.5K | −$67.7K |
| Net margin | 19.9% | 6.5% | -52.0% | -86.7% | — | -35.9% | -208.7% | -21.8% |
| EPS (diluted) | 0.00 | 0.01 | -0.06 | -0.11 | -0.00 | -0.00 | -0.00 | -0.00 |
Annual figures · source: Financial Modeling Prep
GLOBAL PHARMATECH INC
No one on the platform currently holds GBLP.
No tracked institution reports a position in GBLP as of their last filing.
No one on the platform has traded GBLP yet.
| $51M |
| — |
| EVRRFMolecule Holdings Inc. | $0.00 | +0.00% | $626130 | — |
| ISCNFIsracann Biosciences Inc. | $0.00 | +0.00% | $1760 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 101.8× sales vs its 933.6× historical median P/S.
Fair value ≈ $0.73 · price $0.08 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.